Skip to main content

Table 5 The league table for SAE estimates interventions according to their relative effects in first part network analysis

From: Second-line treatment strategy for urothelial cancer patients who progress or are unfit for cisplatin therapy: a network meta-analysis

Apatoren+Taxane (49.6%)#

      

−0.21 (−2.02,1.61)

Icrucumab+Taxane (38.5%)

     

−0.25 (−2.00,1.51)

− 0.04 (− 1.85,1.77)

Pazopanib (36.7%)

    

0.18 (−1.36,1.73)

0.39 (−0.98,1.76)

0.43 (−1.11,1.97)

Ramucirumab+Taxane (59.7%)

   

0.47 (−0.77,1.71)

0.68 (−0.64,2.00)

0.72 (− 0.52,1.96)

0.29 (− 0.63,1.21)

Taxane (79.8%)

  

−0.50 (−2.25,1.24)

− 0.29 (− 2.10,1.51)

−0.26 (− 2.00,1.49)

−0.69 (− 2.22,0.85)

−0.98 (− 2.20,0.25)

Vandetanib+Taxane (24.7%)

 

0.24 (− 1.62,2.11)

0.45 (− 1.47,2.37)

0.49 (− 1.37,2.35)

0.06 (− 1.61,1.73)

− 0.23 (− 1.62,1.16)

0.75 (− 1.11,2.60)

Vinflunine (61.1%)

  1. SAE Severe adverse effect
  2. aThe SUCRA probabilities are performed in brackets
Back to article page

BMC Urology

ISSN: 1471-2490

Contact us